A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
6actual
Sites
4
Countries
Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-08 | actual | When the study began enrolling |
| Primary completion | 2026-04-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-23 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Peripheral T Cell Lymphoma
- Diffuse Large B-cell Lymphoma
- Classical Hodgkin Lymphoma
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Non-Small Cell Lung Cancer
Interventions
- Drug: PF-08046032
- Drug: Sasanlimab
Primary outcomes
what the primary-completion date above is the date OFPart A and Part B: Number of participants with dose limiting toxicities (DLTs) in dose escalation
measured Day of first dose (Day 1) through the end of DLT Observation period (up to 28 days)
All Parts: Number of participants with adverse events (AEs)
measured From first dose (Day 1) through up to 30 days after last dose of PF-08046032 or up to 90 days after last dose of sasanlimab
All Parts: Frequency of dose modifications due to AEs
measured From first dose (Day 1) through up to 30 days after last dose of PF-08046032 or up to 90 days after last dose of sasanlimab
All Parts: Number of participants with clinically significant lab abnormalities
measured From first dose (Day 1) through up to 30 days after last dose of PF-08046032 or up to 90 days after last dose of sasanlimab
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed